Glenmark subsidiary IPO to open next week

Published On 2021-07-21 05:30 GMT   |   Update On 2021-07-21 12:38 GMT
Advertisement

New Delhi: Glenmark Pharmaceuticals on Tuesday said the initial public offering of its subsidiary Glenmark Life Sciences will open on July 27.

On July 19, Glenmark Life Sciences had filed the red herring prospectus for the offer with the Registrar of Companies, Pune and it was taken on record by the ROC the next day, Glenmark Pharma said in a BSE filing.

The proposed offer will have fresh issue worth up to Rs 1,060 crore and sale of up to 63 lakh equity shares by Glenmark Pharma, it added.

Advertisement

Read also: Glenmark to conduct phase 3 trials of nasal spray it claims to be effective in COVID treatment

The offer will open on July 27, 2021 and close on July 29, the filing said.

The expected date of listing is August 6, 2021.

Read also: Glenmark gets CDSCO panel marketing nod to Remogliflozin, Teneligliptin FDC





Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News